SR-16435 is a mixed NOP/μ-opioid partial agonist with equally high affinity (Ki=29 nM) for both NOP and μ-opioid receptors.

SR-16835 is a potent full agonist of ORL1 receptor (NOP receptor) with binding Ki of 11.4 nM, with low-affinity mu-opioid partial agonist activity (Ki=79.9 nM).

SR-20295 (SR20295) is a novel potent ULK1 inhibitor with IC50 of 45 nM..

SR2211 (SR-2211) is a potent, selective RORγ inverse agonist (Ki=105 nM, IC50=320 nM) that potently inhibits production of IL-17 in cells.

SR31527 is a novel allosteric Kinesin-like protein KIFC1 inhibitor that inhibits microtubule-stimulated KIFC1 ATPase activity with IC50 of 6.6 uM, binds directly to KIFC1 with Kd of 25.4 nM.

SR-3306 is a highly selective, brain penetrant, potent inhibitor of JNK with IC50 of 67, 283 and 159 nM for JNK1, JNK2 and JNK3, >100-fold selectivity over p38.

SR3335 (ML-176) is a selective RORα synthetic ligand, directly binds to RORα, but not other RORs, and functions as a selective partial inverse agonist of RORα in cell-based assays.

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR7826 is a potent and selective LIM kinase (LIMK) inhibitor with IC50 of 43 nM, displays >100-fold selectivity over ROCK1 and ROCK2, as well as JNK kinases (>400-fold).

SRI 37892 (SRI37892) is a novel potent, small molecule Frizzled 7 (Fzd 7) inhibitor with IC50 of 0.66 uM in Wnt/β-catenin assay.

SRI-31142 (SRI31142) is a novel potent, putative allosteric dopamine transporter (DAT) inhibitor with Ki of 1.9 nM..

SRPIN-803 (SRPIN 803, SRPIN803) is a novel small molecule dual inhibitor of SRPK1 and CK2 with IC50 of 2.4 uM and 0.2 uM, respectively, does not inhibit SRPK2.

SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.

SRT 2183 is a potent, selective SIRT1 activator with EC1.5 of 0.36 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SRTCX1002 (SRTCX-1002) is a small molecule activator of SIRT1 (STAC) with EC1.5 of 0.4 uM, enhances deacetylation of cellular p65 protein with IC50 of 0.84 uM in cellular p65 acetylation assay.

SRTCX1003 (SRTCX-1003) is a small molecule activator of SIRT1 (STAC) with EC1.5 of 0.61 uM, enhances deacetylation of cellular p65 protein with IC50 of 1.42 uM in cellular p65 acetylation assay.

SSD114 is a novel GABAB positive allosteric modulator.

SSR125543 (Crinecerfont, SSR-125543) is a potent, nonpeptide, orally active corticotropin-releasing factor (CRF) receptor CRF1 antagonist, shows anxiolytic- and antidepressant-like activities in vivo. .

SSR411298 is a highly selective, brain penetrant and orally-active inhibitor of FAAH with IC50 of 62.5 nM (mouse brain FAAH).

SSTC3 is a novel small-molecule CK1α activator with EC50 of 30 nM (WNT-driven reporter gene assay), Kd of 32 nM.